Edition:
United Kingdom

Biocon Ltd (BION.NS)

BION.NS on National Stock Exchange of India

606.90INR
16 Feb 2018
Change (% chg)

Rs5.35 (+0.89%)
Prev Close
Rs601.55
Open
Rs606.00
Day's High
Rs617.70
Day's Low
Rs602.85
Volume
2,240,692
Avg. Vol
3,264,708
52-wk High
Rs657.50
52-wk Low
Rs295.03

Chart for

About

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed... (more)
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

15 Feb 2018

BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE

29 Jan 2018

India's Biocon Q3 profit plunges 46 pct

Jan 24 Biocon Ltd, India's biggest biotechnology firm, posted a 46 percent fall in third-quarter profit on Wednesday hurt by an increase in interest and depreciation costs related to its Malaysia operations.

24 Jan 2018

BRIEF-India's Biocon Dec-Qtr Consol Profit Down About 46 pct

* DEC QUARTER CONSOL PROFIT 919 MILLION RUPEES VERSUS 1.71 BILLION RUPEES LAST YEAR

24 Jan 2018

BRIEF-Biocon Announces Exclusive Global Collaboration With Sandoz On Next-Generation Biosimilars

* ANNOUNCES EXCLUSIVE GLOBAL COLLABORATION WITH SANDOZ ON NEXT-GENERATION BIOSIMILARS'

18 Jan 2018

BRIEF-Biocon And Mylan's Biosimilar Trastuzumab Gets Approval From ANVISA, Brazil

* CO AND MYLAN'S BIOSIMILAR TRASTUZUMAB RECEIVES APPROVAL FROM ANVISA, BRAZIL THROUGH THEIR PARTNER LIBBS

29 Dec 2017

BRIEF-Biocon Says Has Paid Facility Fee For Its API Facility To U.S. FDA

* CLARIFIES ON NEWS ITEM REGARDING CO'S NAME ON FDA LIST FOR NOT PAYING FACILITY FEE

13 Dec 2017

BRIEF-India's Biocon To Transfer Biosimilar Business Via Slump Sale As 'Going Concern' To Biocon Biologics India

* INDIA'S BIOCON SAYS TO TRANSFER BIOSIMILAR BUSINESS THROUGH SLUMP SALE AS 'GOING CONCERN' TO BIOCON BIOLOGICS INDIA - EXCHANGES

07 Dec 2017

FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

The U.S. Food and Drug Administration on Friday approved Mylan NV's biosimilar of Roche's blockbuster treatment for breast cancer, Herceptin, making it the second copycat cancer drug to be approved in the United States.

01 Dec 2017

UPDATE 3-FDA OKs Mylan's biosimilar of Roche cancer drug Herceptin

* Approval ups confidence in Mylan's biosimilar efforts -analysts

01 Dec 2017

Earnings vs. Estimates

No consensus analysis data available.